Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

Market Cap	29.62B -17.4%
Revenue (ttm)	7.07B +8.7%
Net Income	771.46M +129.9%
EPS	0.92 +135.5%
Shares Out	855.14M
PE Ratio	39.50
Forward PE	27.93
Dividend	0.13 (0.32%)
Ex-Dividend Date	Jun 17, 2025

Volume	21,733,351
Open	38.26
Previous Close	38.92
Day's Range	36.05 - 39.86
52-Week Range	36.16 - 71.90
Beta	0.43
Analysts	Buy
Price Target	63.81 (+76.42%)
Earnings Date	Aug 25, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,130
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2025, SHE:300347's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Analyst Summary

According to 17 analysts, the average rating for 300347 stock is "Buy." The 12-month stock price target is ¥63.81, which is an increase of 76.42% from the latest price.

Price Target

¥63.81

(76.42% upside)

Analyst Consensus: Buy